Relmada Therapeutics Reports Q3 2026 Financial Results and NDV-01 Clinical Progress

Relmada Therapeutics (RLMD) reported its third quarter 2026 financial results, highlighting a strengthened cash position of $202.1 million as of September 30, 2026. This liquidity provides a significant capital runway through 2029, which management believes is sufficient to fund the upcoming Phase 3 SPECTRUM studies for its lead oncology candidate, NDV-01. Clinical data from the Phase 2 study of NDV-01 showed strong durability, with an 86% complete response rate at 18 months. The company also reported zero Grade 3 or higher treatment-related adverse events to date. Looking ahead, Relmada expects to submit Investigational New Drug (IND) applications for both NDV-01 and sepranolone by the end of 2026, with Phase 3 patient enrollment projected to begin in Q1 2027.

9 articles from 3 sources · updated

Coverage